2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

101. Red Cells and Erythropoiesis, Excluding Iron: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Treatment Considerations, Supportive Care, Biological Therapies, Antibody Therapy, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Biological Processes, Apoptosis, Pathogenesis, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality of Care, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Neonatal
PAPER

2868 Zanubrutinib in relapsed or refractory warm autoimmune hemolytic anemia: Updated results from a prospective Phase 2 study

Ziwei Liu, MD, Miao Chen, MD2, Bing Han3
1 Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China
2 Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China
3 Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China

Background

Bruton tyrosine kinase (BTK) inhibition is a potential therapeutic strategy for relapsed or refractory warm autoimmune hemolytic anemia (wAIHA). This study aimed to evaluate the efficacy and safety of zanubrutinib in patients with relapsed or refractory wAIHA.

Methods

This prospective, phase 2, single-arm study was conducted at Peking Union Medical College Hospital. Eligible patients were adults with wAIHA or Evans syndrome, hemoglobin <100 g/L, and disease that had relapsed after or was refractory to glucocorticoid treatment. Patients received zanubrutinib 160 mg twice daily, with or without concomitant prednisone at a dose of ≤15 mg/day. The primary endpoint was overall response rate (ORR) at week 12, defined as complete response (CR) or partial response (PR). CR required normalization of hemoglobin and hemolysis markers, whereas PR required a hemoglobin increase of ≥20 g/L from baseline, neither response was impacted by rescue therapy. Safety was assessed in all patients who received at least one dose of zanubrutinib.

Results

Between January 2024 and March 2026, 26 patients were screened and 21 were enrolled, including 17 (81.0%) with wAIHA alone and 4 (19.0%) with Evans syndrome. The median age was 63 years (interquartile range [IQR], 54–69), and 13 patients (61.9%) were female. The median disease duration was 37.2 months (IQR, 19.3–66.8). Patients had received a median of 3 prior lines of therapy (range, 1–8); all had received glucocorticoids, and 13 (61.9%) had received rituximab. Six patients discontinued treatment before week 12 because of adverse events (n=4), loss to follow-up (n=1), or withdrawal of consent (n=1). In the intention-to-treat population, the week-12 ORR was 47.6% (10/21). Among 15 efficacy-evaluable patients at week 12, the ORR was 66.7% (10/15), comprising CR in 5 patients (33.3%) and PR in 5 (33.3%). Median hemoglobin increased from 74 g/L (IQR, 63–86) at baseline to 102 g/L (IQR, 84–124) at week 12, while median total bilirubin decreased from 53.6 to 23.5 μmol/L and median lactate dehydrogenase decreased from 369 to 208 U/L. The median time to first response was 4.0 weeks (IQR, 4.0–5.5). After a median follow-up of 29.4 weeks (IQR, 17.3–71.7), the median observed duration of response was 23.6 weeks (IQR, 13.5–76.8), and no responder had relapsed by the data cutoff. Treatment-emergent adverse events (TEAEs) occurred in 10 patients (47.6%). Grade ≥3 TEAEs occurred in 4 patients (19.0%): grade 4 neutropenia (n=1), grade 3 alanine aminotransferase elevation (n=2), and grade 3 thrombocytopenia (n=1).

Conclusions

Zanubrutinib demonstrated clinically meaningful and rapid hematologic activity in heavily pretreated patients with relapsed or refractory wAIHA, with clinically relevant but generally manageable toxicities. These findings support further evaluation in larger, multicenter studies with longer follow-up.

Ziwei Liu, MD: No relevant conflicts of interest to declare.